The DCI Warren Jones Series Books 1–3. Paul Gitsham

Чтение книги онлайн.

СКАЧАТЬ How would killing Professor Tunbridge make his killer rich? Was Professor Tunbridge particularly wealthy?”

      “No, at least not that I know of. However, Alan’s work was potentially very lucrative.”

      “So, tell me about Professor Tunbridge’s research and why you think it provides a motive.”

      Tompkinson took off his glasses and polished them again, before replacing them and resuming his ‘teacher pose’.

      “Where to start? OK, to fully appreciate how big a motive this is, you need to understand some basic science. I’m sure that you’ve heard about the problems with bacteria becoming resistant to antibiotics? So-called ‘hospital superbugs’ such as MRSA, resistant to even the strongest of antibiotics?” Jones and Hardwick both nodded.

      “Well, the problem cannot be over-stated. There are strains of Staphylococcus aureus, the bacterium that MRSA stems from, that are resistant to all commonly used antibiotics, even the so-called ‘last resort’ drugs such as vancomycin. Let me be clear, here. If you develop an infection from this strain of bacteria, you will die. And it’s not just hospital superbugs. Extreme Drug-Resistant Tuberculosis, or XDRTB, is now being seen in TB hotspots around the globe. The current vaccination against TB, the BCG, is woefully poor and it’ll be years before the latest version comes online. TB is spread by coughing and sneezing. Regular TB still kills millions of people each year. Without antibiotics to kill off the infection, the death rate will soar. These days, a person with TB can pick it up on one side of the world and cough and sneeze his way across the globe in twenty-four hours, infecting everyone he comes in contact with. Can you imagine what it would be like if the strain that the person was carrying was XDRTB?”

      Jones tried to imagine such a scenario and felt a cold chill sweep over him.

      “Of course, drug companies are trying to develop new antibiotics as we speak. however the speed at which bacteria can become resistant to these drugs is frightening. Did you know that the first antibiotic, penicillin, was first used to treat patients in the 1940s yet within four years cases of resistant bacteria were reported? By the 1960s it was present in hospitals and by the end of the 1990s almost forty per cent of Staphylococcus bacteria were resistant. Since penicillin’s discovery, dozens of different antibiotics have been discovered — almost all of which are now resisted by bacteria. Some of those antibiotics were rendered all but useless within ten years. Because of that, there is actually less incentive for drugs companies to invest in new antibiotics.”

      “Huh? You’ve lost me, Professor. Surely with such a need for new antibiotics, whoever discovers a new one stands to make a fortune!”

      Tompkinson smiled sadly. “Unfortunately, it doesn’t work like that. It takes up to a billion US dollars and anything up to fifteen years to develop a new drug. The success rate from good idea to pharmacy counter is tiny. The vast majority of potential drugs are eliminated in the early stages of development because they don’t work or have unacceptable side effects. Drug research is an incredible gamble, with the pay-off being massive exclusive sales in the years before the patent expires after which everyone and his uncle can use your research to make your drug at a fraction of the cost and undercut you. Because of that, pharmaceutical firms favour drugs that will recoup that investment. They like to play safe. So what’s the point of spending a billion dollars developing a new antibiotic that ninety per cent of bugs are going to be resistant to before you’ve even made your investment back?”

      The question hung in the air.

      Scratching his head and trying to keep up, Jones asked the obvious.

      “So where is the motive, then? Presumably anyone stealing his idea would still have to spend millions doing the safety trials. I don’t know much about this sort of thing, but I seem to recall from an article in some Sunday supplement that the bulk of the cost of developing a drug lies with the safety testing. Who is going to murder the prof over something that won’t make them any money?”

      The professor nodded.

      “You are quite right, of course. As regards the bacteria acquiring resistance, rumour has it Professor Tunbridge had solved that particular conundrum.”

      “He’s developed a multi-pronged attack to delay the onset of antibiotic resistance, hasn’t he?”

      The question was blurted out from DC Hardwick.

      Tompkinson nodded enthusiastically as if praising a favourite student.

      “Very good. I see that you know something about this, Constable. Did you study at university before joining the police?”

      She nodded, confidence buoyed somewhat by the praise.

      “Yes, sir. I did a Molecular Biology degree and we learnt a lot about antibiotic resistance. You mentioned that Professor Tunbridge was planning on going commercial with his work — is this what you meant?”

      “Yes, ‘Trident Antibacterials’ was the name he was considering. Alan was just starting to put out feelers for potential backers. It was all very hush-hush, of course. I believe that he was in the process of protecting the work with patents before he went public. The word on the grapevine is that he had successfully developed a drug system that attacked three unrelated drug targets simultaneously. The theory is that whilst the odds of one bacterium developing a chance mutation that renders the cell resistant to an antibiotic is fairly good when you consider the trillions of bacterial cells that will be treated over time, the likelihood of all three targets being thwarted simultaneously is infinitesimal. Even if a cell becomes resistant to one or even two of the methods of attack, the remaining drug target will still remain viable.”

      “So you are saying that Tunbridge’s murder may have been, for want of a better word, industrial espionage?”

      Tompkinson shrugged. “I would say it’s a possibility.”

      “Who would benefit from his death, then, and how?”

      “I suppose the most obvious candidate would be a rival pharmaceutical company. The idea of a multi-pronged attack isn’t in itself brand new. I’ve no doubt that dozens of laboratories around the world are working on similar approaches. Stopping Tunbridge from launching Trident would buy them time.”

      “Murder seems a bit extreme. Why not just buy him out? If the stakes are as high as you say they are, surely somebody could just throw a few million quid his way to sell them his work, or even offer him a job in their company to finish it with them.”

      “That may well have happened. However, knowing Alan as I do, working for another company wouldn’t appeal to his ego. For Alan, being the CEO of his own company that produced this miracle cure would be the ultimate goal. He was a huge self-publicist and he’d have relished the idea of a four-page spread in New Scientist or even the front cover of a major news magazine such as Time. In terms of money, if he wanted to sell his work, then he’d make much more if he was able to sell a fully working product. If it is as successful as he wanted it to be — and it is still a big if — he could float Trident on the stock exchange or even license it to the highest bidder. In this case we could be talking hundreds of millions, if not billions.”

      “What about the research that he has already published? Surely, the cat’s out of the bag now. Isn’t it just a question of time before somebody else follows his work? What about the other members of his lab? Surely, if they got together they could assemble the pieces and finish the work?”

      “Perhaps СКАЧАТЬ